KOD

Business Context and Reporting Period

Kodiak Sciences Inc. (KOD) is a clinical-stage biopharmaceutical company focused on developing transformative therapeutics for retinal diseases. This Form 10-Q covers the quarterly period ended June 30, 2025. The company operates as a single segment and has no products approved for commercial sale. Its primary pipeline includes tarcocimab (anti-VEGF), KSI-501 (bispecific anti-IL-6/VEGF), and KSI-101 (bispecific anti-IL-6/VEGF).

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The filing does not provide specific margin data as the company has no revenue.

Material Changes vs. Prior Period

• Increased R&D Spend: Research and development expenses increased by $10.2 million (31%) for the three months ended June 30, 2025, compared to the same period in 2024. This was driven by increased costs for the GLOW2 and DAYBREAK Phase 3 trials and manufacturing activities for tarcocimab.
• Decreased G&A: General and administrative expenses decreased by $2.7 million (18%) for the quarter, primarily due to lower stock-based compensation and reduced net rent expense following the sublease of a Palo Alto facility.
• Lease Impairment: The company recorded a non-cash lease impairment expense of $1.9 million in Q1 2025 related to the sublease of its 1200 Page Mill Road building, which impacted the YTD G&A comparison.
• Cash Burn: Cash and cash equivalents decreased by approximately $64 million during the first six months of 2025, reflecting continued operational losses.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has stated there is substantial doubt regarding the company's ability to continue as a going concern. The company believes existing cash resources may not be sufficient to meet operating requirements for the 12 months following the report date and plans to raise additional capital.
• Clinical Milestones:
  • GLOW2 (Tarcocimab for DR): Enrollment completed; topline data expected in Q1 2026.
  • DAYBREAK (Tarcocimab & KSI-501 for wet AMD): Actively enrolling; topline data expected in Q3 2026.
  • PEAK/PINNACLE (KSI-101 for MESI): Actively enrolling Phase 3 studies.
• Regulatory Strategy: The company intends to file a single Biologics License Application (BLA) for tarcocimab covering wet AMD, diabetic retinopathy (DR), and retinal vein occlusion (RVO) in 2026, pending successful trial outcomes.
• Key Risks:
  • Failure to obtain additional financing could force the company to pause or discontinue development programs.
  • Historical clinical trial failures (e.g., GLEAM/GLIMMER) highlight the risk of future trials not meeting primary endpoints.
  • Reliance on third-party manufacturers (Lonza) and suppliers for raw materials.
  • Intellectual property challenges and potential patent infringement claims.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any ongoing financing discussions (equity, debt, or collaborations).
• Sublease Impact: Confirm the net impact of the Palo Alto sublease on future rent obligations and the stability of the remaining facility lease.
• Manufacturing Capacity: Assess the readiness of the Lonza "Ursus Facility" and the ability to scale production for commercial launch if approval is granted.
• Stock-Based Compensation: Monitor future stock-based compensation expenses, as the recent decrease was partly due to the vesting of older, higher-value awards.
• Regulatory Feedback: Watch for any FDA feedback regarding the single BLA strategy for tarcocimab across multiple indications.